This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
In postmenopausal women with breast cancer, switching to exemestane increased disease-free survival compared to continuing tamoxifen
Evidence-based Obstetrics and Gynecology. 2005 ;7(2) :103-104
Notes1361259X (ISSN) Cited By: 0; Export Date: 25 May 2006; Source: Scopus CODEN: EOGVA; DOI: 10.1016/j.ebobgyn.2005.01.009 Language of Original Document: English Correspondence Address: Jordan, V.C.; Fox Chase Cancer Center Philadelphia, PA, United States Chemicals/CAS: exemestane, 107868-30-4; tamoxifen, 10540-29-1 References: Jordan, V.C., Tamoxifen: A most unlikely pioneering medicine (2003) Nature Reviews Drug Discovery, 2, pp. 205-213; Tamoxifen for early breast cancer: An overview of the randomised trials (1998) Lancet, 354, pp. 1451-1467, Early Breast Cancer Trialists' Collaborative Group; Fisher, B., Costantino, J.P., Redmond, C.K., Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 (1994) J. Natl. Cancer Inst., 86, pp. 527-537; Goss, P., Strasser, K., Aromatase inhibitors in the treatment and prevention of breast cancer (2001) J. Clin. Oncol., 19, pp. 881-894; Anastrozole alone or in combinationwith tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial (2002) Lancet, 359, pp. 2134-2139, ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trialists' Group; Goss, P.E., Ingle, J.N., Marino, S., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer (2003) N. Engl. J. Med., 349, pp. 1-10.